Johnson & Johnson says recognising the rise of the ePatient and being willing to share its corporate plans with the …

Bristol-Myers’ Squibb’s revenue has fallen 7% year-on-year to $16.4 billion during 2013. Turnover rose 6% to $4.4 billion in the …

The drug designed to be a follow-up to Teva’s wildly successful Copaxone has been hit by rejection in Europe, leaving …

Some nine months after the coalition government’s controversial health reforms came in, have they been a success? And how are …

Biopharma firm PTC Therapeutics has expanded its senior management team with a raft of appointments. Robert Spiegel (pictured) becomes its …

India-based generic manufacturer Ranbaxy Laboratories has been dealt a further blow as the US regulator has banned more of its …

Susan Kilsby is to be the new chairman at Shire and steps into Matthew Emmens’s role as he retires from …

A UK charity is warning the NHS not to write off older cancer patients as ‘too old’ for treatment. With …
The Daily Mail newspaper has backed down on an article it published earlier this month, which alleged that staff at …
The Department of Health is looking to make cheaper generic versions of Pfizer’s Viagra more widely available to patients with …

A senior figure in Denmark’s government has said that local authorities should take legal action against pharma firms which put …
Novartis will shut down a plant in New York State that made heart drug Diovan and malaria treatment Coartem as …

Clinical trials services firm Biotec Services International is looking to expand its presence in the US with the appointment of …

Johnson & Johnson’s sales in the fourth quarter of 2013 rose 4.5% compared to the same period in the previous …

The ABPI has called on the NHS to explain what it says is the ‘substantial variation’ in NHS patients’ access …
A new report has found that Johnson & Johnson is the most engaged pharma company when it comes to using …

Comms and PR consulting firm Hanover has announced senior management changes within its healthcare practice. Andrew Harrison (pictured) takes on …

NICE has recommended Genzyme’s multiple sclerosis pill Aubagio for use on the NHS. In final guidance the watchdog said Aubagio …
Last year the Committee for Medicinal Products for Human Use (CHMP) recommended 81 medicines for marketing approval, compared with just …

Emergent BioSolutions is planning a major expansion of manufacturing capacity for its anthrax vaccine BioThrax to meet the biodefense objectives …